Safety and Biodistribution Evaluation in CNGB3-deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.

@article{Ye2016SafetyAB,
  title={Safety and Biodistribution Evaluation in CNGB3-deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.},
  author={Guo-jie Ye and Ewa Budzynski and Peter Sonnentag and T. Michael Nork and Paul D E Miller and Leslie E. McPherson and James N. Ver Hoeve and Leia Smith and Tara Arndt Arndt and Savitri Mandapati and Paulette Robinson and Roberto Calcedo and David R. Knop and William W. Hauswirth and Jeffrey David Chulay},
  journal={Human gene therapy. Clinical development},
  year={2016},
  pages={
          
        }
}
EVALUATION OF RAAV2TYF-PR1.7-HCNGB3 IN CNGB3 KO MICE. 

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Muscle Gene Therapy

  • Springer International Publishing
  • 2019
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa

  • Molecular therapy. Methods & clinical development
  • 2018
VIEW 1 EXCERPT
CITES RESULTS